AMDHD2

Across TCGA pan-cancer cohorts, AMDHD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AMDHD2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher AMDHD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AMDHD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

UCEC, CCRCC, and HNSC are the cancer types where AMDHD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	0.256	1.000	.002	36	view →
CCRCC	DFS	Quartile	All	1.000	0.542	.021	12	view →
HNSC	DFS	Tertile	II,III,IV	0.914	1.000	.017	7	view →
GBM	OS	Quartile	All	0.227	0.585	.013	6	view →
PDAC	DFS	Tertile	IV	0.182	0.515	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AMDHD2–UCEC (DFS)

Open the UCEC breakdown →